Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Polyganics Ip B V is active in the Chemistry & Materials technology area. The data indicates 2 pending office actions for the company. These actions are located in 2 distinct art units, showing that the current prosecution is not limited to 1 technical area but is instead split between different examination groups.
The company's applications are being reviewed by 2 distinct examiners. The busiest examiner, NGUYEN, HA S, is currently responsible for 1 pending office action. This means the 2 pending office actions are split between the 2 distinct examiners, with each handling 1 case at this time.
With 2 distinct examiners and 2 distinct art units, the prosecution is divided across multiple points of contact. Practitioners can observe that the 2 pending office actions are subject to different perspectives within the Chemistry & Materials sector. This distribution across 2 art units suggests that the company is pursuing multiple technical paths simultaneously, requiring a strategy that accounts for different examiner behaviors.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GHALI, ISIS A D | 2 | 27.9% | +41.6% |
| NGUYEN, HA S | 1 | 58.7% | -21.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18046551 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | 87d overdue |
| 16382652 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18046551 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | 87d overdue |
| 16382652 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 2 |
| 1766 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18188571 | Biomedical Polyurethanes | NGUYEN, HA S | 1766 | §102 | Non-Final OA | — | Pending | Mar 23, 2023 |
| 18046551 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | 1611 | §103§112Other | Final Rejection | 87d overdue | Pending | Oct 14, 2022 |
| 16382652 | Drug Eluting Foams and the Production Thereof | GHALI, ISIS A D | 1611 | §103 | Non-Final OA | — | Pending | Apr 12, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial